Evolving concepts in functional gastrointestinal disorders: Promising directions for novel pharmaceutical treatments

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 16, Issue 6, 2002, Pages 869-883

  Hunt, Richard H ^a   Tougas, Gervais ^b  

^a MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^b Division of Gastroenterology   (Canada)

Author keywords

Functional gastrointestinal disorders; Pathophysiology; Therapeutics

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ACETYLCHOLINE; ANANDAMIDE; BACLOFEN; CANNABINOID RECEPTOR; CHOLECYSTOKININ RECEPTOR; CISAPRIDE; DEXLOXIGLUMIDE; DICYCLOVERINE; DIGESTIVE TRACT AGENT; FEDOTOZINE; HYOSCYAMINE; LOXIGLUMIDE; METOCLOPRAMIDE; MUSCARINIC M3 RECEPTOR; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR; OCTREOTIDE; OPIATE RECEPTOR; PRUCALOPRIDE; RENZAPRIDE; SEROTONIN; SEROTONIN RECEPTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; SUBSTANCE P; TACHYKININ RECEPTOR ANTAGONIST; TEGASEROD; UNINDEXED DRUG; GASTROINTESTINAL AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLINERGIC RECEPTOR BLOCKING AGENT; DELTA OPIATE RECEPTOR AGONIST; DICYCLOMINE BROMIDE; DOMPERIDONE; HYOSCYAMINE SULPHATE; KAPPA OPIATE RECEPTOR AGONIST; MOSAPRIDE CITRATE; MU OPIATE RECEPTOR AGONIST; MUSCARINIC M3 RECEPTOR ANTAGONIST; NEUROKININ A; NEUROKININ B; OPIATE AGONIST; PROGLUMIDE; UNCLASSIFIED DRUG;

ACETYLCHOLINE RELEASE; ADRENERGIC SYSTEM; BRAIN; CENTRAL NERVOUS SYSTEM; CHOLINERGIC SYSTEM; CLINICAL TRIAL; DIGESTIVE SYSTEM FUNCTION DISORDER; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG HALF LIFE; DRUG MECHANISM; DRUG TARGETING; GALLSTONE; GASTROENTERITIS; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL INFECTION; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT FUNCTION; HEART ARRHYTHMIA; HUMAN; HYPERALGESIA; IMMUNITY; INTESTINE INNERVATION; IRRITABLE COLON; NERVE TRACT; NEUROMUSCULAR DISEASE; NOCICEPTION; NONHUMAN; PAIN; PANCREAS DISEASE; PERIPHERAL NERVOUS SYSTEM; QT PROLONGATION; RAT; REVIEW; SENSORY NERVE CONDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOCIAL PSYCHOLOGY; SPINAL CORD; SYMPTOMATOLOGY; AUTONOMIC NERVOUS SYSTEM; GASTROINTESTINAL DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY; ABDOMINAL PAIN; BLOATING; COLON DILATATION; CONSTIPATION; DYSPEPSIA; EVOKED SOMATOSENSORY RESPONSE; HEARTBURN; INTESTINE FUNCTION; INTESTINE MOTILITY; SENSORY NERVE;

AUTONOMIC NERVOUS SYSTEM; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; HUMANS;

EID: 0036886896     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2002.0356     Document Type: Article

References (108)

1. Black, J Q, Duncan, W A, & Durant, C J et al. (1972). Definition of antagonism of histamine H2-receptors. Nature, 236 385-390.
2. Hunt, R H (2002). Evolving concepts in the pathophysiology of functional gastrointestinal disorders. Journal of Clinical Gastroenterology, 35 (supplement): S2-S6.
3. Drossman, D A, Talley, N J, & Leserman, J et al. (1995). Sexual and physical abuse and gastrointestinal illness. Review and recommendations. Annals of Internal Medicine, 123 782-794.
4. Verne, G N, Robinson, M E, & Price, D D (2001). Hypersensitivity to visceral and cutaneous pain in the irritable bowel syndrome. Pain, 93 7-14.
5. Mertz, H, Naliboff, B, & Munakata, J et al. (1995). Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology, 109 40-52.
6. Whitehead, W E, Holtkotter, B, & Enck, P et al. (1990). Tolerance for rectosigmoid distention in irritable bowel syndrome. Gastroenterology, 98 1187-1192.
7. Mertz, H (2002). Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut, 51 (supplement I): i20-i33.
8. Mayer, E A, Naliboff, B D, & Chang, L et al. (2001). Stress and irritable bowel syndrome. American Journal of Physiology-Gastrointestinal Liver Physiology, 280 G519-G524.
9. Barbara, G, Vallance, B A, & Collins, S M et al. (1997). Persistent intestinal neuromuscular dysfunction after acute nematode infection in mice. Gastroenterology, 113 1224-1232.
10. Collins, S M, Hurst, S M, & Main, C et al. (1992). Effect of inflammation of enteric nerves. Cytokine-induced changes in neurotransmitter content and release. Annals of the New York Academy of Sciences, 664 415-424.
11. Vermillion, D L, Ernst, P B, & Collins, S M (1991). T-lymphocyte modulation of intestinal muscle function in the Trichinella-infected rat. Gastroenterology, 101 31-38.
12. Jacobson, K, McHugh, K, & Collins, S M (1997). The mechanism of altered neural function in a rat model of acute colitis. Gastroenterology, 112 156-162.
13. Chadwick, V S, Chen, W, & Shu, D et al. (2002). Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology, 122 1778-1873.
14. Collins, S M (2002). A case for an immunological basis for irritable bowel syndrome. Gastroenterology, 122 2078-2080.
15. Gwee, K A, Graham, J C, & McKendrick, M W et al. (1996). Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet, 347 150-153.
16. McHugh, K J, Weingarten, H P, & Keenan, C et al. (1993). On the suppression of food intake in experimental models of colitis in the rat. American Journal of Physiology, 264 R871-R876.
17. Collins, S M, McHugh, K, & Jacobson, K et al. (1996). Previous inflammation alters the response of the rat colon to stress. Gastroenterology, 111 1509-1515.
18. Mayer, E A, & Collins, S M (2002). Evolving pathophysiologic models of functional gastrointestinal disorders. Gastroenterology, 122 2032-2048.
19. Aggarwal, A, Cutts, T F, & Abell, T L et al. (1994). Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology, 106 945-950.
20. Goyal, R K, & Hirano, I (1996). The enteric nervous system. New England Journal of Medicine, 334 1106-1115.
21. Collins, S M (1996). The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology, 111 1683-1699.
22. Overstreet, D H (1993). The Flinders sensitive line rats: a genetic animal model of depression. Neuroscience Biobehavioural Reviews, 17 51-68.
23. White, A, Stevens, W, & Upton, A et al. (1991). Airway responsiveness to inhaled methacholine in patients with irritable bowel syndrome. Gastroenterology, 100 68-74.
24. Aziz, Q, Furlong, PL, & Barlow, J et al. (1995). Topographic mapping of cortical potentials evoked by distension of the human proximal and distal oesophagus. Electroencephalography and Clinical Neurophysiology: Evoked Potentials, 96 219-228.
25. DeVault, K R, Beacham, S, & Streletz, L J et al. (1993). Cerebral evoked potentials. A method of quantification of central nervous system response to esophageal pain. Digestive Diseases and Sciences, 38 2241-2246.
26. Frieling, T, Enck, P, & Wienbeck, M (1989). Cerebral responses evoked by electrical stimulation of rectosigmoid in normal subjects. Digestive Diseases and Sciences, 34 202-205.
27. Hollerbach, S, Hudoba, P, & Fitzpatrick, D et al. (1998). Cortical evoked responses following esophageal balloon distension and electrical stimulation in healthy volunteers. Digestive Diseases and Sciences, 43 2558-2566.
28. Tougas, G, Hudoba, P, & Fitzpatrick, D et al. (1993). Cerebral-evoked potential responses following direct vagal and esophageal electrical stimulation in humans. American Journal of Physiology, 264 G486-G491.
29. Smout, A J, DeVore, M S, & Castell, D O (1990). Cerebral potentials evoked by esophageal distension in human. American Journal of Physiology, 259 G955-G959.
30. Casey, K L (2000). Concepts of pain mechanisms: the contribution of functional imaging of the human brain. Progress in Brain Research, 129 277-287.
31. Casey, K L, Morrow, T J, Lorenz, J, & Minoshima, S (2001). Temporal and spatial dynamics of human forebrain activity during heat pain: analysis by positron emission tomography. Journal of Neurophysiology, 85 951-959.
32. Naliboff, B D, Derbyshire, S W, & Munakatas, J et al. (2001). Cerebral activation in patients with irritable bowel syndrome and control subjects during rectosigmoid stimulation. Psychosomatic Medicine, 63 365-375.
33. Mertz, H, Morgan, V, & Tanner, G et al. (2000). Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology, 118 842-848.
34. Bernstein, C N, Frankenstein, U N, & Rawsthorne, P et al. (2002). Cortical mapping of visceral pain in patients with GI disorders using functional magnetic resonance imaging. American Journal of Gastroenterology, 97 319-327.
35. Tougas, G, Kamath, M, & Watteel, G et al. (1997). Modulation of neurocardiac function by oesophageal stimulation in humans. Clinical Science (London), 92 167-174.
36. Kamath, M V, May, A, & Hollerbach, S et al. (2000). Effects of esophageal stimulation in patients with functional disorders of the gastrointestinal tract. Critical Review of Biomedicine Engineering, 28 87-93.
37. Bernstein, C N, Niazi, N, & Robert, M et al. (1996). Rectal afferent function in patients with inflammatory and functional intestinal disorders. Pain, 66 151-161.
38. Kamath, M V, & Fallen, E L (1993). Power spectral analysis of heart rate variability: a noninvasive signature of cardiac autonomic function. Critical Review of Biomedicine Engineering, 21 245-311.
39. Haug, T T, Svebak, S, & Hausken, T et al. (1994). Low vagal activity as mediating mechanism for the relationship between personality factors and gastric symptoms in functional dyspepsia. Psychosomatic Medicine, 56 181-186.
40. Hausken, T, Svebak, S, & Wilhelmsen, I et al. (1993). A Low vagal tone and antral dysmotility in patients with functional dyspepsia. Psychosomatic Medicine, 55 12-22.
41. Tougas, G, Spaziani, R, & Hollerbach, S et al. (2001). Cardiac autonomic function and oesophageal acid sensitivity in patients with non-cardiac chest pain. Gut, 49 706-712.
42. Mayer, E, & Gebhart, G F (1994). Basic and clinical aspects of visceral hyperalgesia. Gastroenterology, 107 271-293.
43. Bueno, L, Fioramonti, J, Delvaux, M, & Frxinos, J (1997). Mediators and pharmacology of visceral sensitivity: From basic to clinical investigations. Gastroenterology, 112 1714-1743.
44. Cervero, F, & Laird, J MA (1999). Visceral pain. Lancet, 353 2145-2148.
45. Holzer, P (2001). Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. European Journal of Pharmacology, 429 177-193.
46. Callahan, M J (2002). Irritable Bowel Syndrome Neuropharmacology. A review of approved and investigational compounds. Journal of Clinical Gastroenterology, 35 S58-S67.
47. Kirkup, A J, Brunsden, A M, & Grundy, D (2001). Receptors and transmission in the brain-gut axis: potential for novel therapies. I. Receptors on visceral afferents. American Journal of Physiology - Gastrointestinal & Liver Physiology, 280 G787-G794.
48. Schuurkes, J A, & Van Neuten, J M (1984). Domperidone improves myogenically transmitted antroduodenal coordination by blocking dopaminergic receptor sites. Scandinavian Journal of Gastroenterology, 96 101-110.
49. Richardson, B P, Engel, G, Donatscg, P, & Stadler, P A (1985). Identification of serotonin M-receptor subtypes and their specific blockade by a new class of drugs. Nature, 316 126-131.
50. 4 agonist induces CAMP mediated CI-flux from rat colonocytes. Gastroenterology, 116 A648.
51. 4 agonist [abstract]. Gastroenterology, 117 A643.
52. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Alimentary Pharmacology Therapeutics, 15 1655-1666.
53. Lefkowitz, M P, Rueegg, P C, & Shi, Y et al. (1998). Validation of global relief measure in two clinical trials of irritable bowel syndrome with Tegaserod [abstract]. Digestion, 59 735.
54. Whorwell, P H, Krumholz, S, & Muller-Lisssner, S A et al. (2000). Tegaserod has a favorable safety and tolerability profile in patients with constipation predominant and alternating forms of irritable bowel syndrome [abstract]. Gastroenterology, 118 A1204.
55. Van Outryve, M, Milo, R, & Roussaint, J et al. (1991). "Prokinetic" treatment of constipation predominant irritable bowel syndrome: a placebo-controlled study of cisapride. Journal of Clinical Gastroenterology, 13 49-57.
56. Song, C W, Lee, K y, & Kim, C D et al. (1997). Effect of cisapride and renzapride on gastrointestinal motility and plasma motilin concentration in dogs. Journal of Pharmacology and Experimental Therapeutics, 281 1312-1316.
57. Hardcastle, J, & Hardcastle, P T (1998). 5-Hydroxytyptamine-induced secretion by rat jejunum in-vitro involves several 5-hydroxytryptamine receptor subtypes. Journal of Pharmacy and Pharmacology, 50 39-70.
58. Baber, N S, Dourish, C T, & Hill, D R (1989). The role of CCK, caerulein, and CCK antagonists in nociception. Pain, 39 307-328.
59. Cesselin, F (1995). Opioid and anti-opioid peptides. Fundamentals of Clinical Pharmacology, 9 409-433.
60. Mayer, E A, & Raybould, H E (1990). Role of visceral afferent mechanisms in functional bowel disorders. Gastroenterology, 99 1688-1704.
61. Roberts-Thomson, I C, Fettman, M J, Jonsson, J R, & Frewin, D B (1992). Responses to cholecystokinin octapeptide in patients with functional abdominal pain syndromes. Journal of Gastroenterology and Hepatology, 7 293-297.
62. Kellow, J E, Phillips, S F, Miller, L J, & Zinsmeister, A R (1988). Dysmotility of the small intestine in irritable bowel syndrome. Gut, 29 1236-1243.
63. De Tullio, P, Delarge, J, & Pirotte, B (2000). Therapeutic and chemical developments of cholecystokinin receptor ligands. Expert Opinion Investigational Drugs, 9 129-146.
64. Wiesenfeld-Hallin, Z, & Xu, X J (1993). Role of cholecystokinin type B receptor in nociception studied with peptide agonists and antagonists. In P M Conn (Ed.), Methods in Neurosciences, 148-169. New York: Academic Press.
65. Stein, C (1993). Peripheral mechanism of opioid analgesia. Anesthesia and Analgesia, 76 182-191.
66. Junien, J L, & Wettstein, J G (1992). Role of opioids in peripheral analgesia. Life Sciences, 51 2009-2018.
67. Fioramonti, J, & Bueno, L (2002). Centrally acting agents and visceral sensitivity. Gut, 51 (supplement I): I91-I95.
68. Hassan, A HF, Abletiner, A, Stein, C, & Herz, A (1993). Inflammation of the rat paw enhances neuronal transport of opioid receptors in the sciatic nerve and increases their density in the inflamed tissue. Neuroscience, 55 185-195.
69. Bonaz, B, Riviere, P J, & Sinniger, V et al. (2000). Fedotozine, a kappa-opioid agonist, prevents spinal and supra-spinal Fos expression induced by a noxious visceral stimulus in the rat. Neurogastroenterology and Motility, 12 135-147.
70. Diop, L, Riviere, P, Pascaud, X, & Junien, J L (1994). Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine on the duodenal pain reflex in rat. European Journal of Pharmacology, 257 181-187.
71. Coffin, B, Lemann, M, Fraitag, B, & Jian, R (1995). Effect of fedotozine, a kappa opioid agonist, on gastric visceral nociception in healthy subjects. In J P Galmiche, & B Fraitag (Eds.), Sensitive Gastrointestinal Disorders, 73-76. Paris: John Libbey Eurotext.
72. Delvaux, M (2001). Pharmacology and clinical experience with fedotozine. Expert Opinion Investigational Drugs, 10 97-110.
73. Bouhassira, D, Coffin, B, & Chollet, R et al. (1995). Effect of fedotizine on gastric nociception assessed by a reflexologic technique. Gastroenterology, 108 A576.
74. Read, N W, Bardhan, K D, & Whorwell, P J et al. (1995). Fedotozine in functional dyspepsia: results of a six week placebo controlled multicentre therapeutic trial. Gastroenterology, 108 A676.
75. Delvaux, M, Louvel, D, & Lagier, E et al. (1999). The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology, 116 38-45.
76. 3 receptor antagonists. Life Science, 56 861-868.
77. 3 receptor antagonist one experimental model of bowel dysfunction in vivo. Japanese Journal of Pharmacology, 86 281-288.
78. Pernow, B (1983). Substance P. Pharmacology Reviews, 35 85-141.
79. Payan, D G (1989). Neuropeptides and inflammation: the role of substance P. Annual Review of Medicine, 40 341-352.
80. Krause, J E, DiMaggio, D A, & McCarson, K E (1995). Alterations in neurokinin 1 receptor gene expression in models of pain and inflammation. Canadian Journal of Physiology and Pharmacology, 73 854-859.
81. Collins, S M, Blennerhassett, P, & DeGiorgio, R et al. (1998). The impact of Helicobacter pylori infection on gastric neuromuscular function in the rat: basic observations and clinical implications for our understanding of functional dyspepsia. In R H Hunt, & G NJ Tytgat (Eds.), Helicobacter pylori: Basic Mechanisms to Clinical Cure, 195-208. Lancaster: Kluwer Academic Publishers.
82. Mantyh, C R, Gates, T S, & Zimmerman, R P et al. (1988). Receptor binding sites for substance P, but not substance K or neuromedin K, are expressed in high concentrations by arterioles venules and lymph nodules in surgical specimens obtained from patients with ulcerative colitis and Crohn's disease. Proceedings of the National Academy of Sciences of the USA, 85 3235-3239.
83. Kishimoto, S, Kobayash, H, & Machino, H et al. (1994). High concentrations of substance P as a possible transmission of abdominal pain in rats with chemically induced ulcerative colitis. Biomedical Research, 15 133-140.
84. Morteau, O, & Bueno, L (1994). Viscerosensitivity to colorectal distension is altered during experimental inflammation of rectum in awake rats. Digestive Diseases and Sciences, 39 1239-1248.
85. Kramer, M S, Cutler, N, & Feighner, J et al. (1988). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281 1640-1645.
86. Diemunsch, P, & Grelot, L (2000). Potential of substance P antagonists as anti-emetics. Drugs, 60 533-546.
87. Holzer, P, & Holzer-Petsche, U (1997). Tachykinins in the gut: Part I. Expression release and motor function. Pharmacology and Therapeutics, 73 173-217.
88. Holzer, P, & Holzer-Petsche, U (1997). Tachykinins in the gut: Part II. Roles in neural excitation, secretion and inflammation. Pharmacology and Therapeutics, 73 219-263.
89. Holzer, P (1998). Implications of tachykinins and calcitonin gene related peptide in inflammatory bowel disease. Digestion, 59 269-283.
90. Plourde, V, St-Pierre, S, & Quirion, R (1997). Calcitonin gene-related peptide in viscerosensitive response to colorectal distension in rats. American Journal of Physiology, 273 G191-G196.
91. Holzer, P (1998). Neural emergency system in the stomach. Gastroenterology, 114 823-839.
92. Friese, N, Diop, L, & Chevalier, E et al. (1997). Involvement of prostaglandins and CGRP-dependent sensory afferents in peritoneal irritation-induced visceral pain. Regulatory Peptides, 7 1-7.
93. A receptors on rat vagal afferent neurons. British Journal of Pharmacology, 120 469-475.
94. B receptors. European Journal of Neuroscience, 11 417-426.
95. Dirig, D M, & Yaksh, T L (1995). Intrathecal baclofen and muscimol but not midazolam are antinociceptive using the rat formalin model. Journal of Pharmacology and Experimental Therapeutics, 275 219-227.
96. Yuan, C S, Liu, D, & Attele, A S (1998). GABergic effects on nucleus tractus solitarius neurons receiving gastric vagal inputs. Journal of Pharmacology and Experimental Therapeutics, 286 736-741.
97. B agonist baclofen in normal subjects. Gastroenterology, 118 7-13.
98. 1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Research, 302 73-80.
99. Pertwee, R G (1999). Pharmacology of cannabinoid receptor ligands. Current Medical Chemistry, 6 635-664.
100. Heinmann, A, Shahbazian, A, & Holzer, P (1999). Cannabinoid inhibition of guinea-pig intestinal peristalsis via inhibition of excitatory and activation of inhibitory neural pathways. Neuropharmacology, 38 1289-1297.
101. Izzo, A A, Mascolo, N, & Pinto, L et al. (1999). The role of cannabinoid receptors in intestinal motility, defecation and diarrhea in rats. European Journal of Pharmacology, 384 37-42.
102. Calignano, A, La Rana, G, Giuffrida, A, & Piomelli, D (1998). Control of pain initiation by endogenous cannabinoids. Nature, 394 277-281.
103. Binimelis, J, Webb, S M, & Mones, J (1987). Somatostatin and irritable bowel syndrome. Lancet, 2 1533.
104. Talley, N J, Turner, I, & Middleton, W R (1987). Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet, 2 1144.
105. O'Donnell, L I, Davidson, K, & Cameron, D et al. (1991). Plasma somatostatin concentration in the irritable bowel syndrome. Alimentary Pharmacology and Therapeutics, 5 659-663.
106. Plourde, V, Mertz, B, & Sytnick, Y et al. (1992). Effects of somatostatin analogue on sensory perception to balloon distension. Digestive Diseases and Sciences, 37 976.
107. Hasler, W L, Soudah, H, & Owyang, C (1993). A somatostatin analog inhibits afferent pathways mediating perception of rectal distension. Gastroenterology, 104 1390-1397.
108. Bradette, M, Delvaux, M, & Staurmont, G et al. (1994). Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Digestive Diseases and Science, 39 1171-1178.